Better glycaemic control and less weight gain with once weekly dulaglutide vs bedtime insulin glargine, both combined with thrice daily lispro, in type 2 diabetes (AWARD-4)

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: id:"swepub:oai:DiVA.org:oru-42065" > Better glycaemic co...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Jendle, Johan,1963-Örebro universitet,Institutionen för hälsovetenskap och medicin,Endocrine and Diabetes Center, University of Örebro, Örebro, Sweden (author)

Better glycaemic control and less weight gain with once weekly dulaglutide vs bedtime insulin glargine, both combined with thrice daily lispro, in type 2 diabetes (AWARD-4)

Article/chapterEnglish2014

Publisher, publication year, extent ...

2014-08-19
Springer Science and Business Media LLC,2014
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:oru-42065
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-42065URI
https://doi.org/10.1007/s00125-014-3355-0DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:vet swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Background and aims: This 52 week, parallel-arm, open-label, phase 3 study compared two doses of the once weekly GLP-1 receptor agonist dulaglutide (DU) versus bedtime insulin glargine, all combined with pre-meal insulin lispro with or without metformin, in patients with type 2 diabetes mellitus inadequately controlled on conventional insulin therapy. Insulin glargine and insulin lispro were titrated to attempt to reach glycaemic targets.Materials and methods: Patients (N = 884; mean baseline characteristics: age 59.4 years; duration of diabetes 12.7 years; HbA1c 8.5%; body weight 91.1 kg; BMI 32.5 kg/m2; total daily insulin dose 56 U) were randomised (1:1:1) to once weekly DU 1.5 mg, DU 0.75 mg, or bedtime insulin glargine titrated-to-target. The primary objective was to compare the change in HbA1c from baseline of DU 1.5 mg with insulin glargine at 26 weeks for noninferiority (margin 0.4%) and if met, then superiority was tested.Results: At 26 and 52 weeks, both DU doses were statistically superior to insulin glargine for HbA1c change from baseline. Insulin glargine was associ-ated with greater fasting serum glucose reduction compared with both DU doses. The mean prandial insulin doses at 26 weeks were 93 U for DU 1.5 mg, 97 U for DU 0.75 mg, and 68 U for insulin glargine. The insulin glargine dose was 65 U. Similar insulin doses were observed at 52 weeks. Body weight decreased with DU 1.5 mg and increased with DU 0.75 mg and insulin glar-gine at 52 weeks. The rate of documented symptomatic hypoglycaemia (≤3.9 mmol/L) at 52 weeks was 31.0, 35.0,and 39.9 events/patient/year for DU 1.5 mg, DU 0.75 mg, and insulin glargine, respectively. The number of severe hypoglycaemia events was 11 for DU 1.5 mg, 15 for DU 0.75 mg, and 22 for insulin glargine. Nausea, diarrhoea, and vomiting were more common with DU 1.5 mg (25.8%, 16.6%, and 12.2%, respectively) and DU 0.75 mg (17.7%, 15.7%, and 10.6%) versus insulin glargine (3.4%, 6.1%, and 1.7%).Conclusion: DU compared to insulin glargine, both combined with insu-lin lispro, resulted in better glycaemic control, less body weight gain, no in-creased risk of hypoglycaemia, and more common reporting of gastrointes-tinal adverse events.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

Blonde, L.Ochsner Medical Center, New Orleans LA, USA (author)
Rosenstock, J.Dallas Diabetes and Endocrine Center, Dallas, USA (author)
Woo, V.University of Manitoba, Winnipeg, Canada (author)
Gross, J.Federal University of Rio Grande do Sul, Porto Alegre, Brazil (author)
Jiang, H.Eli Lilly and Company, Indianapolis, USA (author)
Milicevic, Z.Eli Lilly and Company, Vienna, Austria (author)
Örebro universitetInstitutionen för hälsovetenskap och medicin (creator_code:org_t)

Related titles

In:Diabetologia: Springer Science and Business Media LLC57:Suppl 1, s. S23-S240012-186X1432-0428

Internet link

Find in a library

Diabetologia (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Jendle, Johan, 1 ...; Blonde, L.; Rosenstock, J.; Woo, V.; Gross, J.; Jiang, H.; show more...; Milicevic, Z.; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Endocrinology an ...

Articles in the publication: Diabetologia

By the university: Örebro University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se